Nyxoah draws $15m EIB tranche to fund US Genio launch
Nyxoah has drawn down $15 million from the second tranche of its loan facility with the European Investment Bank, bringing total new capital raised in June 2026 to approximately $110 million when combined with a concurrent underwritten public offering. The Belgium-based company, dual-listed on Euronext Brussels and Nasdaq, said the EIB proceeds will be directed primarily at accelerating the commercial launch of its Genio hypoglossal neurostimulation system in the United States.
The Genio system is a leadless, battery-free implantable device intended to treat obstructive sleep apnoea by stimulating the hypoglossal nerve to maintain airway patency during sleep. The device received FDA approval in August 2025, restricted to adult patients with moderate to severe OSA whose Apnoea-Hypopnoea Index falls between 15 and 65. In addition to the US indication, Genio holds European CE marking for an expanded population that includes Complete Concentric Collapse patients, a subset currently contraindicated from treatment with rival neurostimulation devices.
The financing structure
By drawing on non-dilutive EIB debt rather than issuing additional equity, Nyxoah avoids further shareholder dilution while bolstering its balance sheet ahead of what is typically the most capital-intensive phase of a medtech commercialisation: building a US sales force, training implanting surgeons, and securing payer coverage. The structure is consistent with a growing trend among European medtech companies of layering EIB or European Innovation Council debt on top of equity rounds to extend runway without proportionate dilution.
Chief executive Olivier Taelman said the combined financing represented a "transformative" moment for the company and called the EIB's continued involvement "a strong endorsement of our technology." Beyond the US commercial ramp, the company said it will also continue investing in research and development and manufacturing scale-up, though it did not specify capital allocation between these priorities.
Market context and competitive landscape
Nyxoah competes directly with Inspire Medical Systems, whose Inspire upper airway stimulation device has been FDA-approved since 2014 and holds a commanding market position in the US hypoglossal neurostimulation segment. Inspire is significantly more established commercially, with thousands of trained implanting centres across the country. Nyxoah's differentiation argument centres on its leadless, battery-free architecture and the CE-marked CCC indication, the latter of which could theoretically extend the addressable patient population if it is eventually pursued in a US regulatory filing.
The broader OSA device market is attracting renewed attention following years of disruption caused by the large-scale recall of Philips Respironics CPAP and BiPAP devices, which prompted many patients and clinicians to reconsider therapeutic options. That disruption created openings for neurostimulation as an alternative to continuous positive airway pressure therapy, benefiting the category as a whole.
Investors will be watching Nyxoah's US commercial trajectory closely over the coming quarters. Key near-term indicators will include implanting centre activations, procedure volumes, and any progress on expanding the FDA-approved patient population toward the broader indication Genio holds in Europe. The company has not disclosed a specific revenue guidance figure or a timeline for reaching profitability.